Abstract
By 2030, as many as 75 new cell and gene (C&G) therapies may be approved by the FDA. These therapies offer the potential of life-altering cures of sometimes previously untreatable conditions. This paper brings together several related areas of literature concerning C&G therapies to examine their implications for managing population health versus individual patient incentives, access, and outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
